Why Madrigal Pharmaceuticals, Inc. (MDGL) Stock Fell 11.8% on Nov 3, 2026
What happened
Madrigal Pharmaceuticals reported Q3 2026 earnings that beat both earnings and revenue estimates (per Zacks and Globe Newswire), yet the stock fell 5.57% to $407.17 on elevated volume of 891,384 shares (4.87x typical for this time of day). The divergence between positive results and intraday selling suggests investors may have focused on forward guidance or margin concerns rather than the beat itself.
Monitor for analyst commentary and rating changes in the coming sessions; track next earnings date (tentatively February 18, 2027) and watch for any management guidance revisions or pipeline announcements that might explain today's divergent reaction.
Other developments that session
Madrigal Pharmaceuticals, Inc. (MDGL) moved -11.80% from $449.32 to $396.32 on 2026-11-03 after reporting Q3 2026 earnings. MDGL reported EPS of $1.83, beating the consensus estimate of -$0.86 by 312.01%. Volume was elevated at 6.5x the 5-day average.
Madrigal Pharmaceuticals, Inc. (MDGL) reported EPS of $1.83 vs. consensus estimate of -$0.86, beating by 312.1% on November 3, 2026.
Madrigal Pharmaceuticals, Inc. (MDGL) filed a new 10-Q on November 3, 2026.
MDGL reported Q3 EPS of $1.83, beating consensus estimate of -$1.09 loss.
Frequently asked questions
Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock fall on Nov 3, 2026?
Madrigal Pharmaceuticals reported Q3 2026 earnings that beat both earnings and revenue estimates (per Zacks and Globe Newswire), yet the stock fell 5.57% to $407.17 on elevated volume of 891,384 shares (4.87x typical for this time of day). The divergence between positive results and intraday selling suggests investors may have focused on forward guidance or margin concerns rather than the beat itself.
How much did MDGL stock fall on Nov 3, 2026?
MDGL fell 11.8% during the Nov 3, 2026 trading session.
